Robert Hollingsworth

Dr. Hollingsworth joins Shoreline from Pfizer, Inc., where he served as Chief Scientific Officer and Vice President of Cancer Vaccines and Immunotherapeutics. While at Pfizer, Dr. Hollingsworth led a large oncology research team who successfully advanced five programs into clinical development and implemented several innovative new therapeutic approaches. Prior to Pfizer, he was Senior Director, Oncology Research at MedImmune where he led and advanced a large portfolio of more than twenty programs, including CAR-T programs partnered with Juno Therapeutics and the National Cancer Institute, and contributed to the approval of durvalumab (IMFINZI®). Before that, he held several R&D positions of increasing responsibility at GlaxoSmithKline (GSK), Pharmacia and Upjohn.

Dr. Hollingsworth is a decorated scientist with several prestigious awards and honors including the GSK Great Science Award, given to the top R&D scientist each year, and a Research Excellence Team Award at Pfizer for developing an innovative new therapy. Dr. Hollingsworth has published over 50 papers, co-authored over 200 abstracts presented at scientific meetings, and is a co-inventor on over 15 awarded patents. He received a B.A. in Biology and Physics from the University of California, Berkeley, a Ph.D. in Biochemistry, Biophysics, and Genetics from the University of Colorado, and was an American Cancer Society Postdoctoral Fellow at the University of Texas Institute of Biotechnology in San Antonio, Texas.